BACKGROUND: Although millions of people with schizophrenia live in betel chewing regions, the effects of betel chewing on their symptoms are unknown. Betel nut alkaloids include potent muscarinic cholinomimetics: recent research suggests that these agents may be therapeutic in schizophrenia. AIMS: To compare the primary and extrapyramidal symptom profiles and substance-using habits of betel chewing v. non-chewing people with schizophrenia. METHOD: A cross-sectional study of 70 people with schizophrenia. Symptom ratings measured by the Positive and Negative Syndrome Scale (PANSS) and Extrapyramidal Symptom Rating Scale (ESRS), and demographic and substance-use data, were compared for 40 chewers and 30 non-chewers of betel nut. RESULTS: Betel chewers with schizophrenia scored significantly lower on the positive (P = 0.001) and negative (P = 0.002) sub-scales of the PANSS than did non-chewers. There were no significant differences in extrapyramidal symptoms or tardive dyskinesia. CONCLUSIONS: Betel chewing is associated with milder symptomatology and avoidance of more harmful recreational drugs. These initial results indicate that longitudinal research is merited.
BACKGROUND: Although millions of people with schizophrenia live in betel chewing regions, the effects of betel chewing on their symptoms are unknown. Betel nutalkaloids include potent muscarinic cholinomimetics: recent research suggests that these agents may be therapeutic in schizophrenia. AIMS: To compare the primary and extrapyramidal symptom profiles and substance-using habits of betel chewing v. non-chewing people with schizophrenia. METHOD: A cross-sectional study of 70 people with schizophrenia. Symptom ratings measured by the Positive and Negative Syndrome Scale (PANSS) and Extrapyramidal Symptom Rating Scale (ESRS), and demographic and substance-use data, were compared for 40 chewers and 30 non-chewers of betel nut. RESULTS: Betel chewers with schizophrenia scored significantly lower on the positive (P = 0.001) and negative (P = 0.002) sub-scales of the PANSS than did non-chewers. There were no significant differences in extrapyramidal symptoms or tardive dyskinesia. CONCLUSIONS: Betel chewing is associated with milder symptomatology and avoidance of more harmful recreational drugs. These initial results indicate that longitudinal research is merited.
Authors: Yvette C Paulino; Reynolette Ettienne; Rachel Novotny; Lynne R Wilkens; Moria Shomour; Cecilia Sigrah; Shelley D Remengesau; Emihner L Johnson; Julia M Alfred; Daisy F Gilmatam Journal: Cancer Epidemiol Date: 2017-10 Impact factor: 2.984
Authors: Oliver Freudenreich; Lawrence Herz; Thilo Deckersbach; A Eden Evins; David C Henderson; Corinne Cather; Donald C Goff Journal: Psychopharmacology (Berl) Date: 2005-10-14 Impact factor: 4.530
Authors: Caterina Montani; Carola Canella; Adam J Schwarz; Jennifer Li; Gary Gilmour; Alberto Galbusera; Keith Wafford; Daniel Gutierrez-Barragan; Andrew McCarthy; David Shaw; Karen Knitowski; David McKinzie; Alessandro Gozzi; Christian Felder Journal: Neuropsychopharmacology Date: 2020-12-20 Impact factor: 7.853
Authors: Abulimiti Adilijiang; Teng Guan; Jue He; Kelly Hartle; Wenqiang Wang; XinMin Li Journal: Evid Based Complement Alternat Med Date: 2015-02-26 Impact factor: 2.629